Musculoskeletal Ultrasound in Patients With Hematologic Malignancies

NCT07785505 | Not Yet Recruiting

• 1 other identifier: MSK Ultrasound in Blood Cancer
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study evaluates the role and diagnostic value of musculoskeletal ultrasonography (MSUS) in adult patients with hematologic malignancies who present with musculoskeletal symptoms. Hematologic malignancies (such as leukemia, lymphoma, and multiple myeloma) frequently involve the musculoskeletal system through bone marrow infiltration, bone destruction, or soft-tissue lesions. Musculoskeletal ultrasound is a non-invasive, radiation-free, and high-resolution imaging technique that allows real-time evaluation of joints, muscles, tendons, bursae, and superficial bone changes. In this study, adult participants with confirmed blood cancers presenting with symptoms such as localized bone pain, joint swelling, muscle pain, or soft-tissue swelling will undergo a dedicated ultrasound examination of symptomatic areas. The study aims to characterize the patterns of musculoskeletal involvement (including cortical breaks, periosteal changes, soft-tissue masses, synovitis, and vascularity on Doppler imaging) and determine how these findings correlate with disease type, clinical presentation, and laboratory parameters.

Conditions

Hematologic Neoplasms; Leukemia; Lymphoma; Multiple Myeloma; Musculoskeletal Diseases

Keywords

Musculoskeletal ultrasonography; MSUS; Diagnostic imaging; Hematologic malignancies; Power Doppler ultrasound; Synovitis; Periosteal changes; Myeloid sarcoma

Outcome Measures

Primary Outcomes (1)

• Percentage of Participants with Abnormal Musculoskeletal Ultrasonographic Findings

  The percentage of participants exhibiting at least one abnormal sonographic finding on B-mode and color/power Doppler musculoskeletal ultrasound in symptomatic regions. Abnormal findings include cortical breaks/erosions, periosteal elevation/subperiosteal collections, focal soft-tissue or intramuscular masses/infiltrative lesions, joint effusion, synovial thickening/hypertrophy, tenosynovitis, or increased Doppler flow vascularity.

  Baseline

Study Arms (1)

Patients with Hematologic Malignancies

Adult patients (aged 18 years or older) with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) who present with musculoskeletal symptoms (e.g., bone pain, joint pain/swelling, muscle pain, soft-tissue swelling, limitation of movement, or functional impairment) and undergo diagnostic musculoskeletal ultrasonography (MSK-US) with grayscale B-mode and color/power Doppler imaging to evaluate musculoskeletal involvement.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients aged 18 years or older with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) established by bone marrow examination, histopathology, and/or immunophenotyping, identified through the Clinical Hematology Unit registry at Assiut University Hospital, who present with musculoskeletal symptoms and undergo musculoskeletal ultrasound evaluation.

You may qualify if:

• Adult patients (aged 18 years or older) with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) established by bone marrow examination, histopathology, and/or immunophenotyping.
• Patients presenting with musculoskeletal symptoms and undergoing musculoskeletal ultrasonography for the assessment of musculoskeletal involvement at diagnosis or during follow-up.
• Patients willing and able to provide written informed consent.

You may not qualify if:

• Patients with a prior or concurrent solid organ malignancy with known skeletal metastasis.
• Patients with a history of major musculoskeletal trauma, orthopedic surgery, or active musculoskeletal infection affecting the examined region.
• Patients with other connective tissue diseases (e.g., systemic lupus erythematosus, systemic sclerosis).
• Patients with other inflammatory arthropathies (e.g., psoriatic arthritis, ankylosing spondylitis, reactive arthritis).
• Patients with incomplete clinical, laboratory, or follow-up data.
• Patients who decline to participate or withdraw consent.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Hematologic Neoplasms; Leukemia; Lymphoma; Multiple Myeloma; Musculoskeletal Diseases; Synovitis; Sarcoma, Myeloid

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Joint Diseases; Leukemia, Myeloid; Sarcoma; Neoplasms, Connective and Soft Tissue

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident

Study Record Dates

• First Submitted: August 21, 2026
• First Posted: August 25, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): October 1, 2027
• Last Updated: August 25, 2026

Record last verified: 2026-08